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Abstract
Background: A minority of patients presenting with lower respiratory tract infection (LRTI) to their general
practitioner (GP) have community-acquired pneumonia (CAP) and require antibiotic therapy. Identifying them is
challenging, because of overlapping symptomatology and low diagnostic performance of chest X-ray.
Procalcitonin (PCT) can be safely used to decide on antibiotic prescription in patients with LRTI. Lung ultrasound
(LUS) is effective in detecting lung consolidation in pneumonia and might compensate for the lack of specificity of
PCT.
We hypothesize that combining PCT and LUS, available as point-of care tests (POCT), might reduce antibiotic
prescription in LRTIs without impacting patient safety in the primary care setting.
Methods: This is a three-arm pragmatic cluster randomized controlled clinical trial. GPs are randomized either to
PCT and LUS-guided antibiotic therapy or to PCT only-guided therapy or to usual care. Consecutive adult patients
with an acute cough due to a respiratory infection will be screened and included if they present a clinical
pneumonia as defined by European guidelines. Exclusion criteria are previous antibiotics for the current episode,
working diagnosis of sinusitis, severe underlying lung disease, severe immunosuppression, hospital admission,
pregnancy, inability to provide informed consent and unavailability of the GP. Patients will fill in a 28 day-symptom
diary and will be contacted by phone on days 7 and 28. The primary outcome is the proportion of patients
prescribed any antibiotic up to day 28. Secondary outcomes include clinical failure by day 7 (death, admission to
hospital, absence of amelioration or worsening of relevant symptoms) and by day 28, duration of restricted daily
activities, episode duration as defined by symptom score, number of medical visits, number of days with side
effects due to antibiotics and a composite outcome combining death, admission to hospital and complications due
to LRTI by day 28. An evaluation of the cost-effectiveness and of processes in the clinic using a mixed qualitative
and quantitative approach will also be conducted.
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Discussion: Our intervention targets only patients with clinically suspected CAP who have a higher pretest
probability of definite pneumonia. The intervention will not substitute clinical assessment but completes it by
introducing new easy-to-perform tests.
Trial registration: The study was registered on the 19th of June 2017 on the clinicaltrials.gov registry using
reference number; NCT03191071.
Keywords: Lower respiratory tract infections, Procalcitonin, Lung ultrasound, Antibiotic prescription, General
practice, Point of care testing,
Background
As a clear association exists between antibiotic use and re-
sistance rates at community and patient levels, reducing in-
appropriate use is essential [1, 2]. The highest volume of
prescriptions occurs in outpatients presenting with acute
respiratory infections (ARIs) [3, 4]. Amongst these, lower
respiratory tract infections (LRTIs) are the commonest
acute reasons for consulting general practitioners (GPs) [5]
LRTIs include acute bronchitis, exacerbation of chronic ob-
structive pulmonary disease (COPD) and community-ac-
quired pneumonia (CAP). CAP in adults is associated with
high morbidity and mortality rates and requires antibiotic
treatment [6]. Whereas only 5 to 12% of patients presenting
to their GP with LRTIs have CAP, 60% receive an antibiotic
prescription [7, 8].
The absence of specific signs and symptoms for CAP
makes identifying these patients a challenge [9]; in this
context, the presence of a new infiltrate on chest X-ray
supports the definite diagnosis [10]. However, chest X-ray
has several limitations: it is not always readily available at
the GP level [11, 12], exposes patients to radiation and has
a limited diagnostic accuracy for CAP (54% sensitivity and
57% specificity, using chest-CT as a gold standard) [13].
Several studies have evaluated the use of host bio-
markers to help physicians identify patients with re-
spiratory tract infections potentially requiring
antibiotics. Procalcitonin (PCT) and C reactive pro-
tein (CRP) are the most extensively studied. PCT is
more sensitive than CRP in differentiating bacterial
from viral infections in ARIs (respectively 92 and
86%), for a similar specificity (respectively 73 and
70%) [14]. In various settings, including primary care,
the use of PCT to guide antibiotic prescription in
ARIs reduces antibiotic treatment without affecting
outcome [11, 15–17]. Its low specificity in differenti-
ating bacterial from viral aetiologies limits its use in
settings with high rates of viral infections, such as
primary care. More data are required to confirm the
impact of PCT-guided therapy on antibiotic prescrip-
tion rates among patients with LRTIs in primary care.
Lung ultrasound is effective in detecting lung consoli-
dation and has a 92% sensitivity and 93% specificity
using chest-CT as a gold standard for the diagnosis of
CAP [13, 18, 19]. GPs or non-physician respiratory ther-
apists can perform and interpret lung ultrasound after a
short training course [20, 21]. The maximum exam dur-
ation is of 13 min per patient [22]. The high specificity
of lung ultrasound to detect lung consolidation could
potentially compensate the low specificity of PCT.
We hypothesize that the combination of lung ultra-
sound and PCT should improve the accuracy of the
diagnosis of CAP in primary care. To reduce un-
necessary antibiotic prescription without affecting pa-
tient safety, we plan to test a novel simple clinical
management algorithm (UltraPro) integrating the re-
sults of procalcitonin and lung ultrasound used as
point-of-care tests (POCT).
Methods/design
Study objectives
The main objective of the study is to evaluate if the
UltraPro algorithm based on procalcitonin and lung
ultrasound decreases antibiotic prescription amongst
adult patients with LRTIs managed at primary care
level in Switzerland compared to the use of PCT only
and usual care.
The secondary objectives are to compare the clinical
outcome of patients in each arm, to evaluate the accept-
ability and feasibility of the intervention and to calculate
and compare cost-effectiveness between arms.
Study design and setting
This is a three-arm pragmatic cluster randomized con-
trolled superiority trial conducted in GPs practices.
GPs in 6 cantons in Western and central-Western
Switzerland (Bern, Vaud, Neuchâtel, Fribourg, Valais and
Jura) were recruited to ensure representation of different
cultural areas and antibiotic prescription rates [23]. We
chose these regions due to good collaboration between the
investigators and a strong network of GPs during previous
studies, which is essential for the feasibility of the study [24,
25]. The list of the participating GPs can be found in Add-
itional file 1: Table S1.
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Randomization
We will randomly allocate GPs to one of the three
arms of the study: UltraPro, PCT only or usual care.
Randomization with a 1:1:1 ratio between arms
using a computer generated list with variable block
sizes will be performed using the REDCap© elec-
tronic data capture and management tool [26]. Due
to the nature of the intervention, GPs are not
blinded.
Outcomes and hypotheses
The primary outcome is the difference in the proportion
of patients prescribed an antibiotic in each arm by day
28. Table 1 summarizes the secondary outcomes.
Fig. 1 Study design of the randomized intervention study. Abbreviations: PCT: procalcitonin, GPs: general practitioners, ARI: acute respiratory
infection, LRTI: lower respiratory tract infection
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Participants
General practitioners
GPs known to the investigators for their interest in
participating in research and members of local med-
ical societies will be contacted. Study advertising will
also be published in GP’s medical journals.
GPs are eligible if they do not use any of the UltraPro
POCT tests for the management of their patients with a
LRTI in their routine practice. To avoid contamination
between arms, only one GP per practice will be included.
Each participating GP will be responsible for enrolling
15 patients for a maximum period of 15 months.
Patients
GPs will screen for inclusion all adult patients (aged 18
years or older) presenting with a cough due to upper
and/or lower respiratory tract infections. They will in-
clude every consecutive patient meeting the inclusion
and exclusion criteria (Table 2) and providing informed
consent (Fig. 1). GPs are responsible for obtaining in-
formed consent.
Study intervention
Arm 1: UltraPro
The UltraPro algorithm (Fig. 2) combines the results of
a PCT point-of-care test with a lung ultrasound to de-
cide on antibiotic prescription. The medical assistant will
measure PCT using the portable Thermo-Fisher© PCT
Direct rapid point-of-care test. This immunoassay pro-
vides a quantitative PCT result in 20 min using 20 μL of
whole blood. This new device has been validated by
comparison with the reference method (Elecsys® and
Kryptor® B.R.A.H.M.S. PCT assays) with an excellent
correlation index (Pearson’s log-r, r2 = 0.95) [27]. The
measuring range for whole blood samples is 0.22 to
10 μg/l. According to previous studies, a 0.25 μg/L
threshold is safe to decide on antibiotic prescription for
ARIs at primary care level [11, 17, 28].
Table 1 Study outcomes
Primary outcome measure
Proportion of patients prescribed an antibiotic in each arm by day 28
Secondary outcome measures
Clinical outcomes
By day 7
Proportion of patients with clinical failure, defined as:
• admission to hospital OR
• death OR
• absence of amelioration or worsening of relevant symptoms (fever
and/or dyspnoea)
By day 28
Proportion of patients with an adverse outcome, defined as:
• admission to hospital OR
• death OR
complications due to LRTI (persistence of pneumonia, lung abscess,
lung effusion, empyema or sepsis)
Duration of restricted daily activities due to a respiratory tract infection
Duration of the episode (defined by the total daily symptom score)
Number of medical visits for the episode of LRTI
Number of days with side effects related to antibiotics
Consultation process outcomes
• Time spent by the patient in the practice, time required for the
whole consultation
• Patient satisfaction with diagnostic process and consultation
outcome
• Quality of the ultrasound images and of their interpretation
• Provider adhesion, level of trust and perceived usefulness of the
algorithm recommendation
• Identification of barriers and facilitators to the implementation of
UltraPro algorithm in primary care
Economic outcomes
Cost / effectiveness ratio
Table 2 Inclusion and exclusion criteria
Inclusion criteria [10] Exclusion criteria
acute cough (< 21 days) and at least one of the
following sign/symptom:
previous prescription of antibiotics for the current episode
• history of fever for more than 4 days
• dyspnoea
• tachypnoea (> 22 cycles per minute)
• abnormal focal finding upon lung
auscultation
working diagnosis of acute sinusitis or of a non-infective disorder
previous episode of chronic obstructive pulmonary disease exacerbation treated with antibiotics
during the last 6 months
known pregnancy
severe immunodeficiency (untreated HIV infection with CD4 count < 200 cells/mm3, solid organ
transplant receiver, neutropenia (< 1000 cells/μl), treatment with corticosteroids (dose equivalent
to 20 mg prednisone/day for > 28 days)
decision by the GP to admit the patient
GP not available for performing study
patient unable to provide informed consent
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In case of an elevated PCT (≥0.25 μg/L), the GP will
perform a lung ultrasound with a portable L12–4 convex
transducer (Philips© Lumify) to look for the presence of
a lung consolidation (Fig. 2). Lung consolidations are de-
fined as sub-pleural echo-poor regions, sub-pleural re-
gions with a tissue-like echotexture or a focal increase of
B lines [29]. The procedure will follow international evi-
dence-based recommendations for point-of-care lung
ultrasound [29, 30]. We expect the examination to last
10 to 15min.
Only in the presence of an elevated PCT and a lung
consolidation will the algorithm recommend antibiotics
(Fig. 2). The GP will choose the antibiotic, its dosage
and the duration of treatment. The GP is free to order
additional diagnostic tests.
Arm 2: PCT only
The medical assistant will measure PCT using the
POCT assay described above. Only in the presence of an
elevated PCT will the algorithm recommend antibiotics
(Fig. 2). The GP will choose the type of antibiotic, its
dosage and the duration of treatment. The GP is free to
order additional diagnostic tests.
Arm 3: usual care
GPs will manage and treat these patients as they usually
do (Fig. 2).
Physician’s training
GPs in the UltraPro and PCT arms will participate in a
half-day training session. Topics will include antibiotic
resistance, epidemiology of pneumonia in Switzerland,
management of CAP in primary care, the use of PCT
and lung ultrasound to guide antibiotic prescription, the
rationale for the UltraPro algorithm and the procedures
of the study.
GPs in the UltraPro arm will participate in an add-
itional lung ultrasonography half-day training session to
achieve independent practice and appropriately identify
lung consolidation. Topics include ultrasound physics,
ultrasound equipment, probe positioning, image record-
ing and interpretation using a phantom simulator (CAE
Healthcare©). GPs will take a practical exam at the end
of the training session. Three to five months following
the start of the study, we will conduct an extra 2 h lung
ultrasonography training session with inpatients admit-
ted with CAP.
Before patient recruitment, the study team will visit all
GPs at their own practices and train medical assistants
in POCT PCT measurement.
GPs in the usual care arm will receive a two-hour
training on the rationale and the technical procedures of
the study. There will be no training on epidemiology
and management of pneumonia.
Data collection and monitoring
Data collected at inclusion by the GPs include demo-
graphics, co-morbidities, symptoms and their respective
duration, vital and other clinical signs, laboratory tests
and radiologic exams ordered outside the scope the al-
gorithm, PCT result, lung ultrasound interpretation and
antibiotic prescription. GPs will record all ultrasound
images along with relevant metadata.
Study data will be collected via an electronic case re-
port form (eCRF) and managed using REDCap™ elec-
tronic data capture tools hosted at Lausanne University
Hospital [26]. In the UltraPro and PCT arms, medical
assistants will draw venous blood to perform the PCT
POCT measurement.
The study coordinator will perform data monitoring
under guidance from the steering committee that is
composed of the principal investigator, the co-principal
investigators and the co-investigators. The Clinical Trial
Unit of the University Hospital of Lausanne will perform
the external monitoring of the study.
Fig. 2 Description of the three arms of the study. Abbreviations: PCT: procalcitonin; GPs: general practitioners
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Follow-up
A member of the study team (blinded to study arm) will
conduct a standardized phone interview of all partici-
pants on day 7 and day 28. He will record clinical out-
comes (presence or recurrence of LRTIs symptoms),
additional medical visits, additional antibiotic prescrip-
tion, number of days during which activities (work or re-
creation) were restricted, antibiotic side effects,
secondary hospital admission and patient satisfaction.
All participants will fill a validated daily diary until
symptom resolution, up to a maximum of 28 days [31].
They will report each day on six items (cough, phlegm,
shortness of breath, sleep disturbance, impairment of
normal daily activities and feeling unwell) on a Likert
scale (1–6). By summing the values, we will obtain a
daily composite symptom score for each patient.
In case of follow-up visits, GP’s will manage their pa-
tients according to their habitual practice.
Analyses
Sample size calculation
We calculated the sample size to assess an absolute dif-
ference in antibiotic prescription of at least 15% between
each study arm. The steering committee considered this
difference as sufficient to warrant implementation of the
intervention at a larger scale. Sixty % of patients are esti-
mated to receive antibiotics with usual care [8]; we ex-
pect it to be 45% using PCT only and 30% combining
PCT and lung ultrasound.
A study sample of 14 GPs and 15 patients per GP in
each arm (210 patients per arm for a total of 630 patients)
gives a power of 80% to detect the expected difference in
antibiotic prescription with 5% level of significance, when
adjusting for clustering at practice level (intracluster coef-
ficient 0.06) [8]. This sample size also guarantees a power
of 80% to prove non-inferiority in terms of duration of ac-
tivities restriction (non-inferiority margin of 1 day, stand-
ard deviation of 4 days) as well as in terms of the
proportion of patients with adverse outcome by day 28
with an estimated probability in the “usual care” arm of
0.05 (non-inferiority margin of 0.02).
Statistical analyses
The population of all patients included, irrespective of
follow-up will be used for primary data analysis. For pa-
tients who are lost to follow-up we will consider them as
having had clinical failure, an adverse outcome and a
duration of disease to be equal to the maximum mea-
sured in other patients. We will exclude patients whose
GPs did not follow the algorithm recommendation and/
or who did not complete telephone follow-up of the per-
protocol analysis.
The primary analysis will be a logistic regression cor-
rected for variation at GP level (generalized linear mixed
effect) to calculate the difference in the proportion of
patients prescribed an antibiotic by day 28 as well as the
odds ratio of antibiotic prescription between 2 groups.
We will compare secondary outcomes (clinical, con-
sultation process and economic outcomes) between
groups using linear mixed effect regression. We will
compare episode duration between groups using survival
analysis methods.
Qualitative evaluation
Qualitative assessment will be done by face to face semi-
structured interviews with a subset of the participating
GPs. Focus groups will also be conducted with a subset
of the medical assistants. Interview guides for both the
interviews and focus group will focus on needs for train-
ing, feasibility of patient’s recruitment and comfort with
intervention procedures. We will record all semi-struc-
tured interviews and focus groups using standard equip-
ment, transcribed, and coded. Using a content analysis
approach, the transcriptions will be firstly analysed to
identify key themes and to develop a coding frame. Two
different investigators will code independently each tran-
script and compare them for agreement. The coded data
will be analysed and interpreted with regard to the iden-
tification of barriers and facilitators to the implementa-
tion of interventions processes.
Economic evaluation
We will conduct a within-trial economic evaluation and
complement it with a longer-term economic model. All re-
sources involved in the use of the UltraPro algorithm will
be included as intervention costs. These include: 1) human
resources: time spent training GPs and medical assistants,
additional consultation time and additional time spent by
the medical assistant measuring point-of-care procalcitonin,
2) use of health services: referrals to hospital, hospitaliza-
tions, unplanned or planned GP consultations, 3) medical
supplies and equipment: consumables, investment in de-
vices (PCT reader, ultrasonography transducer).
The eCRF will provide most of the data to measure re-
source use. Resource use will be valued using the appro-
priate unit cost, in Swiss Francs (CHF) (e.g. wage rate,
tariff, etc.). The within-trial analysis will involve calculat-
ing the incremental cost-effectiveness ratio, expressed in
CHF per percentage point reduction in antibiotic pre-
scription using the UltraPro algorithm as opposed to
PCT only and usual care. In order to incorporate the po-
tential wider benefits of a reduction in antibiotics pre-
scriptions, such as reduced anti-microbial resistance, we
will design a long-term economic model.
Time plan for the study
Patient recruitment will begin in September 2018 and
last until February 2020.
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Discussion
This will be the first trial to assess POCT PCT measure-
ment as well as its combination with lung ultrasonog-
raphy for deciding on antibiotic prescription in patients
with LRTIs presenting to primary care. Frequent in-
appropriate antibiotic prescription in this population is
in part due to diagnostic uncertainties surrounding the
non-specific clinical presentation of patients with LRTIs
and to the low performance of available radiological
tools. Physicians need better and easily implemented
POCT tools to help them decide on antibiotic prescrip-
tion in this population.
Our study has several strengths. The chosen
randomization level, i.e. GP level, will minimize bias by
avoiding contamination between arms that could occur if
we randomized at patient level. The screening strategy tar-
geting all patients with cough due to an ARI will allow us
to evaluate the proportion of patients with ARIs in whom
CAP is suspected and the overall proportion of ARI pa-
tients receiving antibiotics. These data will allow us to
grasp the potential impact of our intervention from a pub-
lic health perspective. The inclusion criteria are the clin-
ical criteria for suspecting CAP according to European
guidelines. These stringent inclusion criteria guarantee the
reproducibility of the study in various settings and avoid
using the GP’s subjective clinical diagnosis, as done in pre-
vious studies [17]. They also help clinicians in real-life
practice target patients who will benefit from additional
diagnostic tests after their clinical evaluation. As reflected
by our inclusion criteria, our intervention targets only pa-
tients with a higher pre-test probability of definite pneu-
monia. We chose not to include patients with acute
bronchitis or asthma exacerbation as it is established that
such patients do not require antibiotics [32].
The intervention should not substitute clinical assess-
ment; it completes it by introducing new easy-to-perform
tests in case of suspected CAP. Recent studies that did not
show an impact of PCT-guided antibiotic prescription in
LRTIs included patients, for whom antibiotics were not
indicated on clinical grounds alone, thus diluting any po-
tential effect of the intervention [33].
There will be exclusion of a well-defined subset of co-
morbid patients (severe underlying lung disease, severe
immunosuppression, etc. …) who when presenting with
an LRTI should receive antibiotics regardless of clinical
presentation, as there are no data showing that they can
be safely managed using procalcitonin and lung
ultrasound.
As this is a pragmatic trial, the chosen comparator
group is “usual care” rather than standard of care. We
intend to compare our intervention to real life clinical
practice and clinicians in the usual care arm will manage
their patient as per their habitual practice. We consider
that GPs are aware of existing clinical guidelines and
that there are practical and/or pragmatic reasons for not
following recommendations.
There will be a PCT only arm. Although PCT is a sen-
sitive test that can safely reduce antibiotic consumption
among patients with ARIs [11, 16], more data are
needed to confirm its impact on antibiotic prescription
rates when compared to routine setting amongst pri-
mary care patients with LRTIs. We did not include an
additional arm testing lung ultrasound alone as the PCT
pre-screening to decide on lung ultrasonography will
help save time whilst managing the patients and will be
easier to implement at a larger scale in GP practices.
Our study has some limitations. Although we are con-
ducting a pragmatic trial, GP participation is on a volun-
tary basis, leading to inclusion bias. We expect these
motivated and informed GP to have low rates of inad-
equate antibiotic prescription. This could reduce the effect
of our intervention. A reduction in antibiotic prescription
rates in this group could then suggest that the real world
effect would be greater. We also expect that there will be
some deviations from the recommendations of the PCT
only and UltraPro algorithms. To reduce the risk of over-
ruling, we present the rationale behind the algorithms to
the GPs during the half-day training session and exclude
patients who should anyway receive antibiotics when pre-
senting with an LRTI. The possibility of overruling in-
creases the applicability of the findings.
PCT and lung ultrasound are now readily available as
POCT making them easy to implement in primary care
practices. Use rates of point-of-care ultrasonography in
GP practices is variable in Europe [34], it is estimated
that around 30% of Swiss GPs have an ultrasound ma-
chine at their practice (https://www.doctorfmh.ch/) [35]
. This proportion will probably further increase in a near
future due to the development of portable and affordable
machines together with available short training courses.
A pilot study done between December 2017 and April
2018 showed that the implementation of both tools in
the proposed setting was feasible. Decentralization of
the laboratory analyses and radiologic examination to
the GPs practices allows fast and efficient management
of patients with LRTIs, and we believe that both PCT
and lung ultrasound have a role to play in helping physi-
cians prescribe antibiotics adequately in LRTIs.
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